Imaging Study to Measure Tau Protein in the Brain of Adults Over 35 with Progressive Supranuclear Palsy

What this Trial Is About

Researchers are investigating the overall burden of tau protein in the brains of patients with Progressive Supranuclear Palsy PSP. This study aims to better understand how tau accumulates in PSP, which is a progressive brain disorder. The research is led by the Mayo Clinic and involves patients aged 35 and older who show symptoms of PSP. Participants will undergo a Tau PET scan using a tracer called F-18 AV 1451 to image tau protein in the brain. All participants receive this scan as part of the study. The study includes a primary outcome measure focusing on the amount of tau protein detected over a 5-year period, with secondary measures tracking changes in tau burden at baseline and after one year. During the study, participants will be assessed through these imaging scans to observe tau accumulation and progression over time. Researchers will monitor participants for up to five years to evaluate tau protein levels and how they change. The study includes safety considerations such as excluding those with other neurological diseases or conditions that could affect brain imaging results.

A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy